How Biotech and Pharma Companies Actually Choose CROs, CDMOs, and Service Partners

Getting found is only the beginning.

One thing I see all the time working with life sciences companies is how much effort goes into getting in front of potential customers.

More website traffic. More LinkedIn. More conferences. More outbound. More content.

All of those things can help. But they miss a bigger question:

What actually makes a biotech or pharma buyer put one company on the shortlist and pass over another?

For CROs, CDMOs, labs, consultants, technology companies, and other life sciences service providers, the answer is rarely one thing.

A potential customer may hear about you from a colleague, see you at a conference, ask ChatGPT to recommend companies with a specific capability, visit your website, look at your team on LinkedIn, read a case study, and then ask someone they trust if they have ever worked with you.

And all of that can happen before they ever contact you.

That is what has changed.

How Biotech and Pharma companies choose CROs and CDMOs Today?

There isn't one path anymore.

Referrals still matter. Conferences and industry events matter. Google matters. LinkedIn matters. Your existing reputation matters.

Now AI is becoming another part of that mix.

A buyer can ask ChatGPT, Gemini, Perplexity, or another AI tool a very specific question:

• Which U.S. CROs specialize in this assay?

• Who has experience manufacturing this type of biologic?

• Which CDMOs have commercial-scale capabilities and experience with the FDA?

• What companies offer cryo-EM services for drug discovery?

A few years ago, that research might have required dozens of Google searches, recommendations from colleagues, and a spreadsheet.

Now a buyer can have an initial list in minutes.

That doesn't mean AI is making the decision. It means AI may be helping decide who gets looked at in the first place.

Gartner's 2026 B2B buyer research reflects this broader shift. Buyers are increasingly using generative AI to research vendors and products, but they are still turning to people to validate what they find.

That combination is especially important in life sciences.

The search may be digital.

The decision is still very human.

Getting Found Isn't the Same as Getting Shortlisted

This distinction is important.

You can show up in a search result and still lose the opportunity almost immediately.

Once someone finds your company, the next question becomes:

Is this company actually right for us?

That is when buyers start digging deeper.

• Do you understand their science?

• Have you worked on programs like theirs?

• Do you have the right equipment, facilities, capacity, or regulatory experience?

• Can you meet the timeline?

• Who will actually be working on the project?

• What have you done before?

• And, maybe most importantly, can they trust you?

An analysis of searches conducted through an AI-based CDMO sourcing platform showed this progression pretty clearly. Buyers started broad, narrowed potential partners based on increasingly specific requirements, and then moved into direct comparison and validation.

That's much closer to how I see buying happen in the real world too.

Discovery gets you into the pool.

It doesn't win the work.

Your Website Is Part of the Due Diligence

This is one reason I've been talking so much lately about life sciences websites.

Once somebody hears your company name, one of the first things they are going to do is look you up.

And too many life sciences websites make the buyer work way too hard.

I can't tell you how many CRO, CDMO, lab, and life sciences technology websites lead with some version of:

• Scientific excellence.

• End-to-end solutions.

• State-of-the-art capabilities.

• Your trusted partner.

None of that is necessarily wrong. It just doesn't tell me very much.

If I am a buyer, I want to know:

• What are you really good at?

• What kinds of programs do you support?

• Where are you different?

• Have you solved my problem before?

• Why should I trust you with it?

Your website needs to answer those questions quickly.

I wrote recently about why most life sciences websites don't convert because this is exactly the problem I see. Many companies have tremendous scientific credibility. Their websites just don't translate that expertise into a compelling commercial story.

And as more buyer research starts with AI, clarity matters twice: your potential customers need to understand what you do, and AI platforms need enough specific information to understand it too.

Specificity Is Becoming a Competitive Advantage

This may be one of the simplest marketing opportunities in life sciences right now.

Stop saying you have expertise.

Show where the expertise is.

If your scientists have unusual experience with difficult-to-express proteins, talk about it.

If your team has supported dozens of programs involving a specific modality, say so.

If your lab has a capability that most competitors outsource, explain why that matters.

If your team has taken products from early development through commercialization, make that experience easy to find.

If you've solved a difficult technical problem repeatedly, write about the problem.

Specificity makes it easier for a buyer to recognize themselves in your story.

It also gives search engines and AI platforms much more useful information about when your company should appear in an answer.

That's something we covered in more detail in How to Make Your B2B Website Visible in AI-Powered Search.

So Does AI Make Relationships Less Important?

No. I actually think it makes them more important.

AI can help a buyer find you.

It can summarize your capabilities.

It can compare companies.

It can help create a shortlist.

What it can't do is tell someone what it was actually like to work with you when a timeline slipped, an experiment failed, priorities changed, or a difficult decision had to be made.

That is where reputation comes in.

And referrals.

And relationships.

A buyer can do an enormous amount of research online and still end up calling a colleague and asking:

“Have you ever worked with these guys?”

That answer can carry more weight than everything else they just read.

It's something I've seen over and over through BiotechTuesday too. People don't necessarily walk into an event with an active RFP in their pocket. They meet someone.

They have a good conversation. They stay in touch.

Six months later, there is a project.

That's why I don't see AI and networking as competing ideas. I wrote about this recently in Why AI Won't Replace Networking in Biotech and Pharma and How the Best Biotech Partnerships Actually Start.

AI can make discovery much more efficient.

Relationships reduce the risk of the decision.

You need both.

What Actually Gets You Chosen?

If I had to simplify the whole buying journey, I would put it this way:

Visibility gets you discovered.

Buyers need to find you, whether that happens through AI, Google, an event, LinkedIn, an industry article, or a referral.

Clarity gets you considered.

They need to understand quickly what you do, who you do it for, and why your company might be a fit.

Proof gets you shortlisted.

Case studies, scientific expertise, customer examples, regulatory experience, data, publications, facilities, and a credible team give buyers a reason to keep going.

Trust gets you selected.

That's the part that's harder to manufacture. It comes from reputation, referrals, responsiveness, transparency, conversations, and the people behind the company.

You really do need all four.

Stop Treating Marketing and Business Development as Separate Things

This is probably the bigger point.

For CROs, CDMOs, labs, and other companies selling into life sciences, the website, content strategy, events, LinkedIn activity, thought leadership, sales outreach, and relationship building shouldn't operate as separate programs.

To the buyer, they're not separate.

They're all signals.

A buyer may meet you at an event and then visit your website.

They may read an article from one of your scientists and then connect with your BD lead on LinkedIn.

They may discover you through AI and then realize that three people in their network already know your company.

Each touchpoint makes the next one stronger.

We have seen the same thing with events. The value isn't simply collecting leads in a room. The best events create another point of credibility and another opportunity to build a relationship before the customer is ready to buy. That's why I've argued that events can be one of the highest-ROI channels for pharma and biotech service companies.

The companies that do this well don't depend on one campaign to produce a lead.

They build enough visibility and credibility that when the need finally appears, they are already in the conversation.

The Buying Journey Is Changing. The Fundamentals Aren't.

AI is absolutely changing how biotech and pharma buyers research potential partners.

And I think we're still early.

More of the first part of the buying journey is going to happen before a company knows a prospect exists.

But that doesn't mean everything we know about life sciences business development suddenly goes away.

If anything, it puts more pressure on companies to get the fundamentals right.

Be easy to find.

Be clear about what you do.

Give buyers real reasons to believe you.

And build relationships before you need them.

Because whether someone finds you through ChatGPT, Google, a conference, BiotechTuesday, or a recommendation from a former colleague, the goal is ultimately the same:

Be a company that's easy to find, easy to understand, and easy to trust.

Frequently Asked Questions

How Biotech and Pharma companies choose CROs and CDMOs?

Potential partners may be discovered through referrals, industry events, conferences, Google, AI search tools, LinkedIn, scientific publications, existing vendor relationships, and direct outreach. Buyers increasingly use several of these sources before contacting a company. This is how Biotech and Pharma companies choose CROs and CDMOs.

Are biotech and pharma buyers using AI to find vendors?

Yes. AI tools are increasingly being used during B2B research to identify companies, compare capabilities, and answer vendor-selection questions. That makes clear, detailed, authoritative website content increasingly important for life sciences service providers.

How can a CRO or CDMO show up in AI search?

Start with specific content. Clearly describe your services, scientific expertise, modalities, technologies, use cases, facilities, experience, and the problems you solve. Publish useful content around questions your customers actually ask and build authority beyond your own website through industry publications, partnerships, events, and credible third-party mentions.

Is networking still important in biotech business development?

Absolutely. Digital tools can make it easier to discover potential partners, but life sciences remains a relationship-driven industry. Referrals, reputation, industry events, and trusted professional relationships continue to help buyers validate companies and reduce the perceived risk of choosing a new partner.